Adalimumab level and Ab

Test investigation

Adalimumab level and Ab

Laboratory offering test

Referral laboratory

Units

AU/mL

Also known as/Frequency of test

Humira; Exemptia

Indications

Diseases such as ulcerative colitis and Crohn’s disease respond to anti-Tumour Necrosis Factor alpha (TNF-α) therapy (e.g. Adalimumab/ infliximab). During treatment some patients can generate high levels of anti-drug antibodies (ADAs) which negate therapeutic effect. The serum concentration of the drug immediately prior to re-infusion (trough level) is needed to interpret the relevance of ADAs. Please refer to specialist guidelines for monitoring

Comments precautions

Plasma NOT acceptable. Referred outside of EPA

Sample type

Serum

Turnaround times (TAT) Urgent/Routine/GP or OPD

2 weeks

Reference intervals

<5 AU/mL Therapeutic values for Adalimumab (or biosimilar) vary according to pathology